Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ligand Pharmaceuticals (LGND) EBT Margin (2016 - 2025)

Historic EBT Margin for Ligand Pharmaceuticals (LGND) over the last 16 years, with Q3 2025 value amounting to 122.24%.

  • Ligand Pharmaceuticals' EBT Margin rose 1344700.0% to 122.24% in Q3 2025 from the same period last year, while for Sep 2025 it was 25.07%, marking a year-over-year decrease of 135200.0%. This contributed to the annual value of 1.51% for FY2024, which is 469700.0% down from last year.
  • As of Q3 2025, Ligand Pharmaceuticals' EBT Margin stood at 122.24%, which was up 1344700.0% from 23.56% recorded in Q2 2025.
  • Ligand Pharmaceuticals' EBT Margin's 5-year high stood at 366.22% during Q1 2024, with a 5-year trough of 157.45% in Q2 2024.
  • Moreover, its 5-year median value for EBT Margin was 20.86% (2022), whereas its average is 25.01%.
  • In the last 5 years, Ligand Pharmaceuticals' EBT Margin skyrocketed by 2399400bps in 2024 and then crashed by -4769100bps in 2025.
  • Over the past 5 years, Ligand Pharmaceuticals' EBT Margin (Quarter) stood at 31.7% in 2021, then skyrocketed by 51bps to 47.91% in 2022, then increased by 27bps to 60.84% in 2023, then tumbled by -250bps to 91.56% in 2024, then skyrocketed by 234bps to 122.24% in 2025.
  • Its EBT Margin was 122.24% in Q3 2025, compared to 23.56% in Q2 2025 and 110.69% in Q1 2025.